CA04 - Antidody against pancreatic cancer
We have begun the development of an antibody (CA04 project) against a specific target validated in pancreatic cancer.
CA02/03 - Target Identification
CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies
Total Funding Raised - 690K
CancerAppy closed 2021 with €690K total raised.